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Objectives: the long-term outcome in following insertion of inferior vena cava (IVC) filters remains unclear.
Design: prospective study.
Material and Methods: one hundred consecutive patients received percutaneous vena cava filters between 1988 and
1993. The patients underwent clinical examination, abdominal X-rays and duplex ultrasound of the IVC, right internal
jugular vein and legs after a mean follow-up duration of 38±11 months.
Results: forty patients died after implantation (median 11.3 months; IQR: 1.8–20.4 months). The cause of death was
known in 33 cases, and pulmonary embolism (PE) was suggested in three. Multivariate analysis revealed the mortality
rate to be significantly higher in cancer patients (relative risk of 2.13). The 3-year survival was 20% for cancer patients
and 71% for patients without cancer. Among the 60 living patients, thrombi were trapped in the filter in 10 cases, the
filter tilted in four, was malpositioned in five and migrated in 29. These incidents were recorded as asymptomatic
complications, as opposed to seven IVC thromboses and 23 recurrent lower limb thromboses, which were considered as
symptomatic complications.
Conclusion: long-term major complications are not frequent. As expected, cancer was the only factor predicting mortality.
IVC filters seem effective in preventing PE.
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Introduction Materials and Methods
Percutaneous inferior vena cava (IVC) filters have This series of patients was first described in 1993.2
been widely used since they were first described by The data are presented according to the reporting
Tadavarthy in 1984.1 Their use has become even more standards published in 1999.15
frequent as delivery systems have been miniaturised Between December 1988 and April 1993, 100 con-
and application techniques simplified. secutive patients (47 men and 53 women) received a
Previous studies have only reported the short-term percutaneous IVC filter. Their mean age was 68±16
follow-up results from percutaneous filters; most of years (range: 21–91). All patients had deep venous
these were retrospective studies and/or included few thrombosis in the lower extremities, as confirmed by
patients.2–6 The proportion of patients followed up and bilateral contrast venography in 98 patients and by
regularly examined in other studies varies from 30 to duplex in two. The upper level of the initial deep
90%.7–14 venous thrombosis was localised to the IVC in 21
The purpose of this prospective study was to assess, cases, iliac vein in 33 cases, femoral vein in 34 cases,
in a consecutive series of patients, the long-term ef- and below that in 12 cases. Recent pulmonary em-
ficacy and tolerability of these devices, and to identify bolism (PE) was noted in 48 patients on pulmonary
filter-related or unrelated mortality and morbidity angiography or by a high-probability score at per-
factors. fusion lung scan. There was severe obstruction in 27
cases, defined as thrombosis obstructing more than
40% of the pulmonary artery blood flow. The risk
factors are listed in Table 1.
∗ Please address all correspondence to: J.-M. Schleich, Department Indications for filter implantation included a contra-of Cardiology, Centre Cardio-Pneumologique, 2, Rue H. Le Guilloux,
35033 Rennes Cedex 09/France. indication anticoagulatic in 38 patients, PE despite
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Table 1. Predisposing disorders in 100 patients with percutaneous renal vein in another patient. Heparin infusion was
IVC filters.
continued during the procedure and then for 7 days in
Disorder No. of patients patients without contraindications. Oral anticoagulant
treatment was prescribed (in patients without contra-
Malignant tumour 26
indications), for 3–12 months depending on the extentImmobilisation 15
Neurological disease 13 of the clot in the legs and on the presence or absence
Cardiac disease 7 of PE.Orthopaedic injury 11
Impedance plethysmograms, duplex sonograms ofPrevious phlebitis 16
Obesity 2 the lower extremities and IVC, perfusion scans of the
No 10 lungs, and standard abdominal X-rays were performed
in all patients 1–2 days after filter insertion.
All patients alive (n=86) 3 months after filter in-
sertion were examined. This included physical ex-
amination, digital-subtraction cavograms in frontal
and lateral projections, impedance plethysmograms,
abdominal radiographs in frontal and lateral views,
perfusion lung scan from six different angles, and
duplex sonograms of the lower extremities and IVC.
In the first 50 patients CT scans were performed only
when an IVC perforation was detected by cavography.
CT scans were systematically performed in the re-
maining 50 patients. The results obtained have already
been reported.2
One year after the latest patient in the series was
Fig. 1. Side views of a Filcard filter (left) and a Cardial filter (right). treated by IVC filter insertion (May 1994), we elected
The Filcard filter is constructed in the shape of a six-ribbed umbrella
to track those 100 patients, with a view to submittingand composed of “Elgiloy” (cobalt-base high-strength alloy). The
Cardial filter is constructed in the shape of an eight-ribbed umbrella them to physical examination, standard abdominal
and made of stainless steel. Hooks on the struts limit filter movement frontal and lateral X-rays, duplex sonograms of the
within inferior vena cava.
lower extremities, right internal jugular vein and IVC
venography. If a PE was clinically suspected, a per-adequate anticoagulation in 29 patients, chronic cor
fusion lung scan from six different angles was per-pulmonale in five patients, and prophylaxis in 28
formed and compared with the previous one. It tookpatients. The latter patients were at higher risk of
27 months to carry out these tests in all survivingPE because of free-floating IVC thrombi (evolutive
patients (May 1994–September 1996).thrombi as observed on two different examinations),
Duplex sonograms were obtained using an Ultra-or because of chronic lung disease or heart failure. All
mark 9 model (Advanced Technology Laboratories,patients gave their informed consent.
Seattle, U.S.A.), in the longitudinal and transversalFilters were inserted percutaneously under local
planes with a 3.5, 5, and 7.5 MHz electronically focusedanaesthesia through the right internal jugular vein.
linear-array transducer.An IVC venogram was performed using a 5 F catheter
Abdominal X-rays were performed immediatelyto assess the size of the IVC and to determine the
after filter placement, at 3 months and throughout theposition of the renal veins. In each case, the operators
long-term follow-up, using the same magnifying rateattempted to place the top of the filter cone at the
for accurate comparison of filter diameter. An increaselevel of the lower renal vein. The position of the
>2 mm or a decrease <4 mm in filter diameter withoutfilter was checked on cavography at the end of the
migration, were considered as indicative of IVC per-procedure. The entire procedure took 20–30 min. One
foration and IVC thrombosis, respectively. Filter dis-hundred and four filters were placed: 65 Filcard filters
placement >5 mm was considered as a significant(Filcard International, Lille, France), and 39 Cardial
migration. Imaging studies were interpreted by twofilters (Cardial, St Etienne, France) (Fig. 1). The type
independent reviewers.of filter depended solely on the operator’s choice. Four
If any patient died, the patient’s GP, cardiologistpatients received two filters. This was because of IVC
and family were interviewed on the circumstances ofduplication in one patient, extensive thrombus more
their death and any events occurred since the latestthan 5 cm long above the top of the filter after 3 months
in two patients, and filter misplacement into the right out-clinic visit.
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Table 2. Causes of death in 40 patients during the follow-up
period.
Cause No. of patients
Malignant tumour 18
Suspected recurrent PE 3
Disease
Cardiac 7
Neurological 5
Pulmonary 1
Sepsis 1
Suicide 1
Unknown 4
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For statistical analysis, the Chi-squared test was
Fig. 2. The life-curve obtained by actuarial method of Kaplan–Meierused for non-parametric data and Student’s t-test for shows the probability of mortality during follow-up. The mean
parametric values. Kaplan–Meier’s actuarial method value is represented by the solid line and the confidence interval
superior and inferior by the dashed-lines. Arrows and n valueswas used to calculate the probability of mortality
express the number of patients recorded at the various times ofduring follow-up. Life curves were compared using a follow-up, as read on the X axis.
Log-rank test. The Cox test was used for multivariate
analysis. Probability values of 5% or less were con-
sidered as statistically significant. Table 3. Anticoagulant treatment in 60 surviving patients.
Anticoagulation treatment No. of patients
Results No treatment 40
Oral 16
Low molecular weight heparin 2No patient was lost to follow-up. A comparative study Unknown 2
of complications according to the type of filter elicited
only one difference: IVC perforation was less frequent
with the Filcard model (20%) than with the Cardial
model (59%) (p<0.0001).2 The results of both types of Surviving patients
filters in the whole of group studied are presented
together. All 60 surviving patients (33 women and 27 men; mean
age: 71±13 years; range: 31–92) were re-examined at
a mean follow-up of 38±11 (range: 12–57) months.
Two patients had two IVC filters implanted becauseDeceased patients
of vena cava duplication in one and a misplaced filter
in the other. Cancer was discovered in one of theseForty patients (18 men and 22 women) died within 7
days to 39 months following filter implantation (me- patients 6 months after filter insertion.
Oral anticoagulant treatment was administered todian 11.3 months; IQR: 1.8–20.4 months). Their mean
age at death was 67±15 years (range: 24–92). The 16 patients without any major complication. Forty
patients had no anticoagulant treatment and twocauses of death are summarised in Table 2. Twenty-five
patients had not been given anticoagulant treatment patients received subcutaneous heparin because of
recent recurrent phlebitis of the legs. For two patients,before their death. Eight patients were receiving hep-
arin infusion or subcutaneous heparin when they died, it was not known whether they received anticoagulant
treatment or not (Table 3).one of them probably of recurrent PE despite ad-
equately administered anticoagulant treatment. Oral Bilateral oedema of the lower limbs was found in
13 patients and oedema on the side of the initial deepanticoagulant treatment was given to seven patients:
six suffered no complication whatsoever and one died venous thrombosis was noted in another 20 patients.
Twenty-seven of the surviving patients permanentlyof recurrent PE.
The results, as computed by Kaplan–Meier’s ac- wore elastic stockings. Trophic disease, initially pres-
ent in six patients, was noted in 14 (23%) and varix,tuarial method, show that the survival probability at
6 months and at 1, 2, and 3 years was 83, 78, 67 and initially present in 11 patients, was noted in 19 patients
(32%) at the end of follow-up. Venous ulcer smaller62%, respectively in the overall experimental group
(Fig. 2). than 5 cm2 was noted in three patients.
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Pulmonary embolism
Perfusion lung scan, performed in all patients 3 months
after filter insertion, demonstrated three asympto-
matic/pulmonary embolisms. Pulmonary embolism
was suspected to be the cause of death in three of
the deceased patients (see above). In another patient
(seventh patient), ultrasonography performed 2 years
after filter implantation revealed a trapped thrombus
extending above the top of the filter and perfusion
lung scan demonstrated an asymptomatic PE. No clin-
ical sign of recurrent PE was noted in the whole group
of patients, but imaging was not systematically used
after 3 months in this study to objectively rule out
recurrent emboli, and therefore asymptomatic silent
PE may have been overlooked at clinical follow-up.
In another 13 patients where clinical PE was suspected,
long-term follow-up perfusion lung scan was normal
and ruled out the initial PE diagnosis. As a result, the
exact rate of recurrent PE following filter insertion is
not known.
Radiographic data
Abdominal X-ray with both frontal and lateral views
Fig. 3. Four months after implantation. Standard anteroposterior
were performed as part of the long-term follow-up of X-ray shows complete rupture of the filter into two equal parts.
49 patients (82% of surviving patients). In total, 29
filter migrations (5–20 mm) were noted, including four
new long-term migrations, three in the cranial dir- Ultrasonographic data
ection and one in the caudal direction. Twenty-six of
the 5–20 mm migrations were caudal. Cranial mi- Long-term follow-up duplex US was performed in
44 surviving patients (73%). This examination wasgrations were shorter and less frequent (three cases).
None of these migrations produced any clinical symp- performed by the same experienced operator in 41
patients. Internal jugular vein analysis revealed onlytoms. Spontaneous rupture of the filter into two equal
parts was noted 4 months after insertion in one patient two cases of minor stenosis without any haemo-
dynamic effect. Another complete IVC occlusion in-(Fig. 3). This patient underwent annual clinical ex-
amination, abdominal X-ray and duplex US as part of cluding the filter was noted in two patients, bringing
to seven the overall number of complete IVC occlusionsfollow-up, and after 6 years the filter is stable with no
complications.16 at the end of long-term follow-up, including five cases
recorded at 3 months. No significant relationship wasAt the end of follow-up, no new filter tilting >30°
was observed in addition to the four cases recorded found between the incidence of IVC and the existence
or duration of anticoagulant therapy. Another partialat 3 months, and none of these patients presented with
PE. IVC occlusion or “trapped” thrombus was observed
in one patient, bringing the overall number of partialA further 2-mm reduction of filter diameter was
noted in seven patients. In three of them, it was IVC occlusions at the end of long-term to 10, nine of
which were recorded at the 3-month follow-up visit.associated with filter migration to an IVC segment
whose diameter was different from that of the im- According to Cox’s model, none of the following
factors were related to IVC or filter patency duringplantation site and in another two it was associated
with complete IVC occlusion. A filter diameter increase the follow-up period: age, sex, level of initial deep
vein thrombosis, type of filter and filter insertion sitein excess of 2 mm was observed in two patients, in-
cluding one where it was associated with filter imposed by anticoagulant contraindication.
In total, 23 cases of recurrent deep vein thrombosismigration.
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Discussion
Long-term follow-up of patients treated with IVC
filters is difficult because of their age, poor general
condition, and because most are asymptomatic.
As noted by other authors, 20%–45% of patients
(mean: 30%) died within the first year following filter
implantation.5,8,9,12 That mortality rate was mainly
linked to cancer, which appeared to be the only pre-
dicting prognostic factor in this study. However, 1
year after filter insertion the life curve slopes of both
groups of patients, i.e. with and without cancer, be-
came similar (Fig. 4), hinting at the role of filter in-
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sertion in cancer patients with favourable prognosis,
Fig. 4. The comparison of the life-curves obtained by actuarial although this is difficult to identify at that stage.method of Kaplan–Meier and using a Log-rank test shows the
Considering the limited life expectancy of patientsprobability of mortality during follow-up in patients with cancer
(thick lines for mean and standard deviation) and in patients without with advanced malignancies, the appropriateness of
cancer (thin lines for mean and standard deviation). Arrows and n IVC filter placement may be questioned. High mor-values express the number of patients recorded at the various times
of follow-up, as read on the X-axis. tality rates have been reported in patients with
advanced malignancies who were implanted with IVC
filters,6,10,17 and the presence of metastatic cancer has
were recorded, localised at the caval (n=2), iliac (n= been classified as a relative contraindication to IVC
2), femoral (n=3), and lower (n=16) levels. The two filter insertion.18,19 However, that contradicts other re-
recurrent deep vein thromboses at the caval level ports which underlined the usefulness of filters in
did not reach the filter. The existence or duration of cancer patient care.20–23 Indeed, several authors have
anticoagulant therapy after filter insertion did not suggested that cancer patients with acute deep venousinfluence the incidence of recurrent deep vein throm-
thrombosis need systematic implantation of definitivebosis. Six cases of recurrent deep vein thrombosis were
percutaneous IVC filters, rather than anticoagulantnoted in patients with complete IVC occlusion. In 16
treatment, to decrease haemorrhagic risks and thecases (70%), deep vein thrombosis recurred in the
incidence of recurrent PE.22,23 Despite the poor prog-same leg as the initial thrombotic episode.
nosis of patients with advanced malignancy, filterTen filter-trapped thrombi, four filter tiltings >30°,
placement is advocated if anticoagulant treatment isfive misplacements (one patient with two filters), and
contraindicated, which is often the case in this type of29 filter migrations >5 mm were recorded as asympto-
patient. Although mortality rates at 12 months seemmatic complications. Seven IVC thromboses and 23
to be very high, patients appear to benefit from therecurrent leg phlebites were recorded as symptomatic
filter for the remainder of their lives.complications. Anticoagulant treatment did not in-
The cost-benefit ratio is more difficult to establish.fluence the incidence of these complications. Re-
We believe that indications for this particular groupgarding the subgroup of cancer patients, the diagnosis
of patients must be debated on a case-by-case basis bywas known at the date of insertion in 26 patients,
the medical staff. PE, being a rare occurrence (observedand in the course of follow-up in another two cases.
probability range: 0%–6%), has little influence on theEighteen of these patients died during the study (64%).
overall mortality rate,4,6,7,9–12,14,24–26 but when PE doesDeath was directly related to cancer in 13 of the
recur the outcome is fatal in 25%–60% of cases.6,12,25deceased patients. Mean life span was 10±8 months
In our study we observed seven possible cases ofin cancer patients vs 14±12 months in patients without
PE. This rate was higher than in other series. However,cancer.
we systematically performed a perfusion lung scanMultivariate analysis showed that the mortality rate
at the 3-month follow-up visit in all patients. Wewas significantly increased only in cancer patients,
uncovered four cases of asymptomatic PE and retainedwith a relative risk=2.13; 95% confidence interval:
PE as the probable cause of death in three patients,1.03 to 4.4; p<0.04. These results, computed by Kaplan–
although the exact cause of death could not be preciselyMeier’s actuarial method, show that the probability to
determined.be alive at 6 months, 1, 2, and 3 years was 65%, 50%,
In other series the mortality rate only takes symp-38% and 20% in cancer patients and 89%, 87%, 76%
and 71% in cancer-free patients, respectively (Fig. 4). tomatic PE into account, i.e. diagnosed on the basis of
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clinical symptoms. That rate was therefore probably Although IVC occlusion rarely causes severe com-
plications of venous stasis, further studies on its effectunder-estimated in those series because routine follow-
up imaging, perfusion lung scan or pulmonary angio- in younger patients with longer life expectancy would
be required. Indeed, Crochet et al. noted that PE withgraphy were not performed in asymptomatic patients.
No significant correlation was found in this series anticoagulation failure before filter insertion was pre-
dictive of IVC occlusion during follow-up.28between the use of anticoagulant treatment and the
recurrence of PE or between patients with and without Only few literature reports have described thrombi
trapped in IVC filters, although they may be the causeIVC occlusion. David et al. reported that recurrent
PE was more frequent in patients with procoagulant of recurrent PE, usually asymptomatic.7 The main
problem is the difficulty to discriminate between asyndrome (protein C or S or AT III) and advocated
lifetime warfarin treatment for these patients.26 genuine and a trapped thrombus, the former reflecting
the thrombogenicity of the filter and the latter itsAssuming that the vena cava filter is properly
placed, the mechanism of PE is related either to pro- effectiveness. Thrombi within the filter are reported
in 0%–39% of patients.2,7,8,10 As reported in a previouspagation of a thrombus through the luminal openings
of the filter, or to emboli travelling through collateral study, the detection of trapped thrombi depends on
the imaging evaluation methods.2venous pathways, or to a thrombus extension above
the filter if the vena cava is completely obstructed by Like other authors, we noted that long-term anti-
coagulant therapy was not related to thrombus pres-a thrombus or embolus coming from the superior vena
cava. In the latter case, a superior vena cava filter can ence in the filter.8 Nevertheless, the purpose of
anticoagulant treatment in patients with vena cavabe implanted.
It does appear, from comparisons with control filters is to limit further extension of a thrombus. In
that situation, anticoagulant treatment should limitpatients, that vena cava filters are effective for the
prevention of PE, if anticoagulant treatment is not the number of emboli trapped by the filter and decrease
the probability of complete caval obstruction or throm-indicated.
Filter placement through the right internal jugular bus propagation through the filter. Unfortunately, anti-
coagulant contraindication is precisely one of the mainvein did not induce any complication in any one of
our patients, except two minor stenoses without any indications for vena cava filter implantation. A throm-
bus trapped in the filter may reduce the flow rate,haemodynamic effect. To our knowledge, no long-
term study has analysed the right jugular vein patency. resulting in filter and vena cava retraction. What hap-
pens to thrombi within the filter is not well known.When the femoral vein was used as the access
site, early thrombosis was a major complication Unfortunately, specific, longer-term follow-up of our
patients with this complication was not possible. Fobbewith the Kimray–Greenfield filter (rate range: 10% to
56%).4–6,8–10,27 et al. recorded thrombi trapped within the filter in 39%
cases with spontaneous lysis in 31% cases and anThe purpose of this prospective study was to assess,
in a consecutive series of patients, the long-term ef- extension less than 2 cm above the top of the filter in
25%.10 To facilitate clot lysis, we have kept implantingficacy and tolerance of these devices and to determine
whether mortality factors and rate depended on the the top of the filter cone at the level of the lower renal
vein, although it has not been demonstrated that thistype of filter and on the duration of follow-up. Crochet
et al. showed that vena cava patency dropped from approach is optimal.
A migration <5 mm may often be attributed to dif-92% after 2 years of follow-up to 80% after 4 years,
and to 70% after 6 years.11 In previous publications, ferences in patient posture, breathing and parallax of
the roentgen beam. We observed 29 cases of migrationwe observed that all IVC thromboses had been de-
tected either by venacavogram, or computed tomo- >5 mm. Most occurred within the first 3 months fol-
lowing filter implantation (86%). Migrations did notgraphic scan, or duplex sonograms16; therefore the
diagnostic rate does not depend on the type of ex- induce any clinical symptoms and all were detected
only at follow-up X-ray study. Nevertheless, severalamination performed. Like Crochet et al., we observed
that filter retraction was linked to IVC thrombosis at cases of migration into the right heart cavities or
pulmonary arteries have been published.30 These casesthe filter level.28 In this study we noted, as did other
authors, that long-term anticoagulant treatment fol- could be related to the failure of filter anchoring
components in the IVC wall.lowing filter insertion was not correlated with IVC
thrombosis.8,28 Tardy et al. noted that early IVC filter We recorded four cases of filter tilting >30°. All
were observed during the first week following filterthrombosis was due to intracaval extension of DVT
and they emphasised the need for appropriate anti- implantation. With the Greenfield Stainless filter, tilt-
ing by more than 15° occurred in 7–17% of cases.8,14coagulant treatment.29
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The lowest rate of filter tilting observed in our series side-effects. They represent alternatives to anti-
coagulant treatment when such a therapy is contra-was obtained with the Filcard model, similar to the
LGM filter, and was probably due to the effectiveness indicated, complicated by haemorrhage, or fails to
prevent PE or extensive DVT. However, because ofof its six vertical legs, which ensure its centering into
the IVC.11,14 these possible complications it is recommended that
a permanent IVC filter be inserted only after discussionSpontaneous rupture of the filter strut has been
noted in 1–2% of patients.7,16,24,31 However, some studies with the medical staff. Long-term follow-up studies
and improved devices remain necessary.35 Temporaryhave reported a 27–77% incidence of filter rupture in
patients with the Anthe´or, Gu¨nther and Simon Nitinol IVC filters appear to be an interesting alternative
method in specific situations, but these still need tomodels.7,12,32 That rupture was usually spontaneous
and due to metal fatigue associated with the continual be rigorously and accurately evaluated.36
stress applied to the filter. To our knowledge, this is
the only report of a complete filter rupture in two
equal parts with a 6-year follow-up free of com-
Acknowledgementsplications.16 The wide incidence variability of this com-
plication according to the type of filter justifies that The authors thank Philip Rousseau-Cunningham for English proof-
each case be recorded in a national register, especially reading.
with the new IVC filters.
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